The £1 million grant will support the development of the first Oral Food Challenges (OFCs) for paediatric patients to diagnose peanut, milk, and egg allergies. Food allergy (FA) prevalence and hospitalisations are rising, especially in young children. Families face death from anaphylaxis, social exclusion, reduced quality-of-life (QoL), and out-of-pocket costs >£2489/year. A coming wave of […]
Pursuant to a capital raise in 2020, Reacta has achieved its goal of securing an MHRA site license This license opens up significant opportunites for the companies core Oral Food Challenge Diagnostic platform Reacta Biotech, a clinical diagnostic company dedicated to providing innovative diagnostics for life-threatening food allergies, today announced that its manufacturing facility in […]
Deeside-based Reacta Biotech is on course to secure a market authorisation for its peanut diagnostic product within the next two years as global activity to treat peanut allergies accelerates.